Mumbai (Maharashtra) [India], May 18: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730)is pleased to announce the launch of “HORMONE RANGE PRODUCTS, its premium specialty therapeutics brand focused on longevity, hormone health, recovery science, and human performance solutions. The initiative marks Fredun’s strategic entry into a rapidly expanding, high-value healthcare segment driven by increasing global demand for preventive, performance-oriented, and precision-based therapeutics.
Built on a doctor-led, ethical, and evidence-backed pharmaceutical model, the hormone range products combine clinical credibility with a digital-first patient/doctor engagement ecosystem to deliver an integrated healthcare experience focused on outcomes, adherence, and long-term patient value. The range is designed to address the growing shift from traditional disease management towards healthy lifespan optimization, preventive care, and advanced performance therapeutics.
Strategic Highlights
·Strategic expansion into high-growth longevity and specialty hormone therapeutics
·Doctor-led and evidence-backed platform focused on clinical outcomes
·Premium positioning in hormone health, recovery science, and performance care
·Digital + Pharma hybrid model enabling end-to-end patient engagement
·Focused on precision-driven, high-margin, and differentiated therapeutic categories
·The range of products will work hand in hand with our protein supplement range and help
strengthen our reach within the existing demographic, while enabling us to offer a more comprehensive approach towards preventive healthcare, wellness, and performance therapeutics
The initial portfolio includes therapies and formulations based on testosterone and its salts, nandrolone, growth hormone-oriented solutions, and supportive hormone optimization therapies, developed to meet specialised clinical requirements under appropriate medical supervision. The platform is further supported by protocol-driven patient monitoring, doctor engagement, and direct-to-patient fulfillment capabilities designed to improve treatment continuity and patient adherence.
The brand leverages Fredun Pharmaceuticals Limited’s established strengths in pharmaceutical formulation development, quality-focused manufacturing, and global distribution capabilities, while creating new opportunities in premium, innovation-driven therapeutic segments. ADARO is positioned to build a differentiated presence through scientific quality, regulatory alignment, premium product experience, and clinically guided treatment pathways.
Core Business & Growth Drivers
·Premium, science-driven therapeutic positioning
·Focus on hormone optimization and preventive healthcare
·Digital-led patient acquisition and retention strategy
·Specialised formulations with strong clinical orientation
·Direct-to-patient engagement and subscription-based continuity model
·Expansion into emerging high-growth healthcare categories
With increasing consumer and medical focus on vitality, metabolic health, recovery science, and preventive wellness, Fredun believes its hormone range products are well-positioned to address an evolving market opportunity through a trusted, outcomes-focused, and ethically driven pharmaceutical approach. The launch further reinforces the Company’s long-term vision of building a diversified and future-ready healthcare portfolio spanning both large-scale generics and advanced specialty therapeutics.
Commenting on the development, Mr. Fredun Medhora, Managing Director, Fredun Pharmaceuticals Limited said: “The launch of our hormone range products represents a significant milestone in our journey towards building a more specialised and future-ready pharmaceutical portfolio. As we move up the value chain, our focus is on entering segments that demand high scientific rigor, clinical validation,and manufacturing excellence. This range reflects our vision by bringing together medical expertise andevidence-based formulations to create a credible presence in hormone and performance therapeutics.”
About Fredun Pharmaceuticals Limited
Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company’s objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
In the FY25, Fredun reported total revenues of ₹ 456 Cr, with an EBITDA of ₹ 55 Cr and a PAT of ₹ 21 Cr.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
rss_feed
Disclaimer:This content is sourced from syndicated feeds, PR agencies, or brand submissions. Views expressed are those of the respective authors, and we do not independently verify them..
PNN
(This story has been published from a syndicated feed, agency source, or press release. NewsWaala Team may not have edited or verified the content independently.)
